Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16070 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Sathya Narayanan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Lung Neoplasms, Drug Monitoring. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Therapeutic drug monitoring (TDM) has led to significant improvements in individualized medical care, although its implementation in oncology has been limited to date. Tyrosine kinase inhibitors (TKIs) are a group of therapies for which TDM has been suggested. Osimertinib is one such therapy used in the treatment of epidermal growth factor receptor (EGFR) mutation‐driven lung cancer. Herein, we describe a prospective pilot study involving 21 patients on osimertinib primarily as a preliminary evaluation of drug levels in a real‐world setting.
Methods
Concentrations of the drug and its primary metabolites were measured with a validated liquid chromatography–mass spectrometry (LC–MS) assay across serial timepoints. As part of this study, inter‐individual variability by dose and ethnicity as well as intra‐individual variability across timepoints are explored. Furthermore, we attempted to validate dried blood spot (DBS)‐based quantitation as an accurate alternative to plasma quantitation.
Results
Successful quantitation of osimertinib and primary metabolites was achieved for our subjects. Compound plasma levels were highly correlated to DBS levels. There was no significant difference in concentrations with ethnicity or dosing or intra‐individual variability across timepoints.
Conclusions
As such, we demonstrate that TDM for osimertinib is practical for future trials. We also validated the use of DBS as an alternative to conventional quantitation for exploration of TDM for osimertinib in larger trials and for other targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia.
- Macquarie University Clinical Trials Unit, Macquarie University, Sydney, NSW, Australia.
- School of Medicine, University of Sydney, Sydney, NSW, Australia.
- Kolling Institute of Medical Research, Sydney, NSW, Australia.
- School of Medical Sciences, University of Sydney, Sydney, NSW, Australia.
- Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
ORCID-Profile: Sathya Narayanan
Zitieren
APA
Narayanan, S., Yuile, A., Venkatesh, B., McKay, M., Itchins, M., Pavlakis, N., Wheeler, H., Gray, L., Wei, J., Miller, S., Kirwin, B., Molloy, M. P., & Clarke, S. (2024). Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16070
Vancouver
Narayanan S, Yuile A, Venkatesh B, McKay M, Itchins M, Pavlakis N, et al. Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16070
BibTeX
@article{Narayanan2024,
author = {Narayanan, Sathya and Yuile, Alexander and Venkatesh, Bharat and McKay, Matthew and Itchins, Malinda and Pavlakis, Nick and Wheeler, Helen and Gray, Lauren and Wei, Joe and Miller, Samuel and Kirwin, Brendan and Molloy, Mark P and Clarke, Stephen},
title = {Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16070}
}
EUVIMED